Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®
Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment to support the clinical program with Modufolin®, Isofol’s lead drug candidate. Modufolin® is a novel folate-based compound being developed to increase the efficacy and reduce the side effects of chemotherapeutic agents used in the treatment …
